BTAI_OUT_1 [2025-03-19 12:20:28 -0400] 2346 Bytes | 646 tokens | Cum: 646 tkns (8.08% of 8k)
==========================================================================

Listen up, partner—it's 12:20:27 PM on Wednesday March 19, 2025 ET (UTC-0400), and I’m revved up about BioXcel Therapeutics (BTAI), climbing from 2.2 to 2.5401. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for BioXcel Therapeutics:

C1 - Mar-11-25 07:00AM - BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
C2 - Mar-09-25 06:05PM - Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week
C3 - Mar-07-25 07:00AM - BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
C4 - Mar-04-25 04:15PM - BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
C5 - Mar-04-25 04:15PM 10:00AM - BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
C6 - Mar-03-25 03:33PM - BioXcel Therapeutics Announces $14 Million Registered Direct Offering
C7 - Mar-03-25 03:33PM 07:00AM - BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia
C8 - Feb-28-25 07:00AM - BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about BioXcel Therapeutics (BTAI)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of BioXcel Therapeutics.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

BTAI_OUT_3 [2025-03-19 12:20:31 -0400] 969 Bytes | 300 tokens | Cum: 948 tkns (11.85% of 8k)
==========================================================================

Showing C1 (chunk 1 of 15): C1:
**BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia**
Date: Mar-11-25 07:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/11/3040398/0/en/BioXcel-Therapeutics-Strengthens-Cash-Position-to-Advance-SERENITY-At-Home-Pivotal-Phase-3-Safety-Trial-for-Acute-Treatment-of-Agitation-Associated-with-Bipolar-Disorders-or-Schizo.html

March 11, 2025 07:00 ET| Source:BioXcel TherapeuticsBioXcel Therapeutics

Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI®in the home setting

Company has $35M of cash following closing of recent equity financing

NEW HAVEN, Conn., March 11, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical c

-- More? (MOR) or Next section? (NEX)

BTAI_OUT_5 [2025-03-19 12:20:32 -0400] 980 Bytes | 208 tokens | Cum: 1158 tkns (14.47% of 8k)
==========================================================================

Showing C1 (chunk 2 of 15): ompany utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that, following the successful raise of $14 million gross proceeds in an equity financing that closed on March 4, 2025, it has approximately $35 million in cash. The strengthened cash position will support continued advancement of the Company’s pivotal Phase 3 SERENITY At-Home trial. The trial is designed to evaluate the safety of BXCL501, BioXcel Therapeutics’ investigational, proprietary, orally dissolving film formulation of dexmedetomidine, in the at-home setting for the acute treatment of agitation associated with bipolar disorders or schizophrenia.

“We are pleased the recent financing enables us to progress our SERENITY At-Home trial,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “Patient enrollment is continuing and topline data results expected in the second hal

-- More? (MOR) or Next section? (NEX)

BTAI_OUT_7 [2025-03-19 12:20:34 -0400] 975 Bytes | 213 tokens | Cum: 1373 tkns (17.16% of 8k)
==========================================================================

Showing C1 (chunk 3 of 15): f of 2025 are intended to support a potential sNDA submission to expand the label for IGALMI®in the at-home setting. We are highly motivated by the prospect of bringing — for the first time — an acute treatment option for agitation to millions of additional patients in this setting.”

The SERENITY At-Home Phase 3 trial is a double-blind, placebo-controlled study designed to evaluate the safety of a 120 mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the home setting. The trial is enrolling 200 patients with a history of agitation episodes residing at home either alone or with caregivers/informants. Patients will self-administer 120 mcg of BXCL501 or placebo when agitation episodes occur over the 12-week trial period, with safety data (adverse events) collected during the trial. Patients or caregivers/informants will complete

-- More? (MOR) or Next section? (NEX)

BTAI_OUT_9 [2025-03-19 12:20:35 -0400] 961 Bytes | 285 tokens | Cum: 1665 tkns (20.81% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-11T12:44:26Z - BioXcel Therapeutics strengthens cash position to advance SERENITY trial...
A2 - 2025-03-11T12:07:38Z - BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Tr...
A3 - 2025-03-11T11:23:01Z - BioXcel Therapeutics (BTAI) Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Sa...
A4 - 2025-03-11T11:00:20Z - BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Tr...
A5 - 2025-03-11T10:38:46Z - North American Morning Briefing: Stock Futures -2-...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BTAI_OUT_11 [2025-03-19 12:20:37 -0400] 967 Bytes | 247 tokens | Cum: 1914 tkns (23.93% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**BioXcel Therapeutics strengthens cash position to advance SERENITY trial**Date: 2025-03-11Source: {'uri': 'markets.businessinsider.com', 'dataType': 'news', 'title': 'Markets Insider'}URL: https://markets.businessinsider.com/news/stocks/bioxcel-therapeutics-strengthens-cash-position-to-advance-serenity-trial-1034463292BioXcel Therapeutics (BTAI) announced that, following the successful raise of $14 million gross proceeds in an equity financing that closed on March 4, 2025, it has approximately $35 million in cash. The strengthened cash position will support continued advancement of the Company's pivotal Phase 3 SERENITY At-Home trial. The trial is designed to evaluate the safety of BXCL501. "We are pleased the recent financing enables us to progress our SERENITY At-Home trial," said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. "Patient enrollment is continuing and topline data

-- More? (MOR) or Next section? (NEX)

BTAI_OUT_13 [2025-03-19 12:20:39 -0400] 390 Bytes | 92 tokens | Cum: 2008 tkns (25.10% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): results expected in the second half of 2025 are intended to support a potential sNDA submission to expand the label for IGALMI(R) in the at-home setting. We are highly motivated by the prospect of bringing - for the first time - an acute treatment option for agitation to millions of additional patients in this setting."

-- More? (MOR) or Next section? (NEX)

BTAI_OUT_15 [2025-03-19 12:20:41 -0400] 1127 Bytes | 334 tokens | Cum: 2349 tkns (29.36% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-11T11:00:00Z - BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
B2 - 2024-11-21T21:47:12Z - BioXcel Therapeutics Announces Proposed Public Offering
B3 - 2024-11-21T21:47:00Z - BioXcel Therapeutics Announces Proposed Public Offering
B4 - 2024-07-16T11:02:51Z - BioXcel Therapeutics Announces Preliminary Estimated - GlobeNewswire
B5 - 2024-04-24T14:30:00Z - BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
B6 - 2024-03-25T11:00:00Z - BioXcel Therapeutics Announces $25 Million Registered Direct Offering

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BTAI_OUT_17 [2025-03-19 12:20:48 -0400] 954 Bytes | 247 tokens | Cum: 2598 tkns (32.48% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/11/3040398/0/en/BioXcel-Therapeutics-Strengthens-Cash-Position-to-Advance-SERENITY-At-Home-Pivotal-Phase-3-Safety-Trial-for-Acute-Treatment-of-Agitation-Associated-with-Bipolar-Disorders-or-Schizo.htmlBioXcel Therapeutics has strengthened its cash position to $35 million, which will support the advancement of its SERENITY At-Home pivotal Phase 3 trial for the acute treatment of agitation associated with bipolar disorders or schizophrenia. The company expects topline data in the second half of 2025 to support a potential sNDA submission for label expansion of IGALMI® in the home setting.

-- More? (MOR) or Next section? (NEX)

BTAI_OUT_19 [2025-03-19 12:20:50 -0400] 558 Bytes | 151 tokens | Cum: 2860 tkns (35.75% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S5 - 2025-03-04 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 3, 2025, BioXcel Therapeutics, Inc. (the Company) entered into a securities purchase agreement (the Purchase Agrmt) with the purchaser named therein (the Purchaser). Pursuant to the Purchase Agrmt, the Comp...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

BTAI_OUT_21 [2025-03-19 12:20:51 -0400] 967 Bytes | 244 tokens | Cum: 3106 tkns (38.82% of 8k)
==========================================================================

Showing S5 (chunk 1 of 5): S5:
Item 1.01. Entry into a Material Definitive Agreement.

On March 3, 2025, BioXcel Therapeutics, Inc. (the Company) entered into a securities purchase agreement (the Purchase Agreement) with the purchaser named therein (the Purchaser). Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchaser and the Purchaser agreed to buy in a registered direct offering (the Offering) (i) an aggregate of 188,383 shares (the Shares) of common stock, par value $0.001 per share (Common Stock) and accompanying warrants to purchase up to 188,383 shares of Common Stock at a combined offering price of $3.50 per Share and accompanying warrant, and (ii) pre-funded warrants (the Pre-Funded Warrants) to purchase up to 3,811,617 shares of Common Stock and accompanying warrants to purchase up to 3,811,617 shares of Common Stock, at a combined offering price of $3.499 per share un

-- More? (MOR) or Next section? (NEX)

BTAI_OUT_23 [2025-03-19 12:20:53 -0400] 967 Bytes | 217 tokens | Cum: 3325 tkns (41.56% of 8k)
==========================================================================

Showing S5 (chunk 2 of 5): derlying the Pre-Funded Warrants and accompanying warrant, which equals the offering price per Share and accompanying warrant less the $0.001 exercise price per share of the Pre-Funded Warrants, pursuant to an effective registration statement on Form S-3 (File No. 333-275261), including the base prospectus included therein, and prospectus supplement filed with the Securities and Exchange Commission (SEC) on March 4, 2025. In the Offering, the Company also issued to the Purchaser warrants (the Option Warrants), to purchase up to 4,000,000 shares of Common Stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 4,000,000 shares of Common Stock to the Purchaser. The pre-funded warrants and accompanying warrants issuable upon exercise of the Option Warrants will have substantially identical terms as the Pre-Funded Warrants and the accompanying warrants. The

-- More? (MOR) or Next section? (NEX)

BTAI_OUT_25 [2025-03-19 12:21:02 -0400] 5023 Bytes | 1389 tokens | Cum: 4716 tkns (58.95% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+--------------------+-----------------------+------------------------+--------------------------+-------------------------+
| Prev Close: 2.20 | RSI (14): 45.68 | Perf Quarter: -62.09% | Insider Trans: -6.38% | Sales Q/Q: -37.24% | ROE: -1766.94% |
+---------------------+--------------------+-----------------------+------------------------+--------------------------+-------------------------+
| Target Price: 49.25 | ATR (14): 0.69 | Index: - | Option/Short: No / Yes | Sales past 5Y: 67.00% | ROI: -374.29% |
+---------------------+--------------------+-----------------------+------------------------+--------------------------+-------------------------+
| Price: 2.50 | SMA20: 3.29% | Market Cap: 8.23M | Short Float: 12.06% | Income: -71.00M | Sales Surprise: -83.88% |
+---------------------+--------------------+-----------------------+------------------------+--------------------------+-------------------------+
| Change: 13.63% | SMA50: -35.37% | Shs Outstand: 3.29M | Short Ratio: 0.07 | Employees: 74 | EPS Surprise: 36.70% |
+---------------------+--------------------+-----------------------+------------------------+--------------------------+-------------------------+
| Volume: 3,528,813 | SMA200: -75.57% | Shs Float: 2.74M | Short Interest: 0.33M | Debt/Eq: - | P/E: - |
+---------------------+--------------------+-----------------------+------------------------+--------------------------+-------------------------+
| Avg Volume: 4.70M | Perf Week: 2.88% | Inst Own: 16.42% | Beta: 0.60 | Sales Y/Y TTM: 83.25% | Earnings: Nov 14 BMO |
+---------------------+--------------------+-----------------------+------------------------+--------------------------+-------------------------+
| Rel Volume: 1.76 | Perf Month: 10.13% | Insider Own: 16.85% | Sales: 2.28M | Profit Margin: -3119.33% | |
+---------------------+--------------------+-----------------------+------------------------+--------------------------+-------------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: BioXcel Therapeutics, Inc. (BTAI) by Mehta Vimal (CEO and President) on 2025-03-14
- Common Stock: 162 shares at $N/A (D)
- Common Stock: 217 shares at $N/A (D)
- Restricted Stock Units: 162 shares at $0 (D)
- Restricted Stock Units: 217 shares at $0 (D)

Inside Trans: BioXcel Therapeutics, Inc. (BTAI) by Yocca Frank (Chief Scientific Officer) on 2025-03-14
- Common Stock: 31 shares at $N/A (D)
- Common Stock: 34 shares at $N/A (D)
- Restricted Stock Units: 31 shares at $0 (D)
- Restricted Stock Units: 34 shares at $0 (D)

Inside Trans: BioXcel Therapeutics, Inc. (BTAI) by Rodriguez Javier (See Remarks) on 2025-03-14
- Common Stock: 31 shares at $N/A (D)
- Common Stock: 34 shares at $N/A (D)
- Restricted Stock Units: 31 shares at $0 (D)
- Restricted Stock Units: 34 shares at $0 (D)

Inside Trans: BioXcel Therapeutics, Inc. (BTAI) by Steinhart Richard I (Chief Financial Officer) on 2025-03-14
- Common Stock: 31 shares at $N/A (D)
- Common Stock: 34 shares at $N/A (D)
- Restricted Stock Units: 31 shares at $0 (D)
- Restricted Stock Units: 34 shares at $0 (D)

Inside Trans: BioXcel Therapeutics, Inc. (BTAI) by MACK DAVID J. (Unknown Title) on 2025-02-28
- Common Stock: 1693 shares at $N/A (D)
- Restricted Stock Units: 1693 shares at $0 (D)

Inside Trans: BioXcel Therapeutics, Inc. (BTAI) by MACK DAVID J. (Unknown Title) on 2025-01-31
- Common Stock: 27089 shares at $N/A (D)
- Restricted Stock Units: 27089 shares at $0 (D)

No transactions recorded.

Inside Trans: BioXcel Therapeutics, Inc. (BTAI) by Patni Rajiv (Unknown Title) on 2025-01-15
- Stock Option (right to buy): 44000 shares at $0 (D)

Inside Trans: BioXcel Therapeutics, Inc. (BTAI) by Yocca Frank (Chief Scientific Officer) on 2025-01-07
- Stock Option (right to buy): 270000 shares at $0 (D)

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

BTAI_OUT_27 [2025-03-19 12:21:04 -0400] 561 Bytes | 131 tokens | Cum: 5069 tkns (63.36% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More financial metrics
-> X3 <- More SEC filings & insider data
-> X4 <- Broader sector & market news
-> X5 <- General market sentiment & AI confidence levels
-> X6 <- AI's past analysis on similar companies
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

BTAI_IN_29 [2025-03-19 12:21:05 -0400] 126 Bytes | 29 tokens | Cum: 5105 tkns (63.81% of 8k)
==========================================================================

====================================
[2025-03-19 09:21:05] # Analysis Completed
Elapsed Time: 39.07 seconds